McKesson (MCK)
(Delayed Data from NYSE)
$498.48 USD
+4.06 (0.82%)
Updated Oct 1, 2024 04:00 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Revenue - Line of Business Segments | YR Estimate | 03/31/2023 | 03/31/2022 | 03/31/2021 | 03/31/2020 | 03/31/2019 |
---|---|---|---|---|---|---|
Revenue: U.S. Pharmaceutical [$M] |
-- | 240,616 | 212,149 | 189,274 | 181,700 | 167,763 |
Revenue: Prescription Technology ... |
-- | 4,387 | 3,864 | 2,890 | 2,705 | 2,489 |
Revenue: Medical-Surgical Solutio... |
-- | 11,110 | 11,608 | 10,099 | 8,305 | 7,618 |
Revenue: International [$M] |
-- | 20,598 | 36,345 | 35,965 | 38,341 | 38,023 |
Income - Line of Business | YR Estimate | 03/31/2023 | 03/31/2022 | 03/31/2021 | 03/31/2020 | 03/31/2019 |
Adjusted Operating Profit: U.S. P... |
-- | 3,106 | 2,932 | 2,717 | 2,628 | 2,520 |
Adjusted Operating Profit: Prescr... |
-- | 679 | 590 | 467 | 468 | -- |
Adjusted Operating Profit: Medica... |
-- | 1,159 | 1,204 | 805 | 679 | 605 |
Adjusted Operating Profit: Intern... |
-- | 498 | 702 | 485 | 461 | 219 |
Adjusted Operating Profit: Corpor... |
-- | -457 | -579 | -584 | -640 | -555 |